A discussion on how to apply updated data from ESMO 2021 to treatment decisions for patients with HR+/HER2- advanced breast cancer.
EP. 1: Identifying PIK3CA Mutations in HR+ HER2- MBC
October 11th 2021Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.